204
Participants
Start Date
October 31, 2006
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
Levonorgestrel (Mirena, BAY86-5028)
Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
Cytotec
Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
Placebo
Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
Turku
Quetigny
Tampere
Jyväskylä
Roanne
Reims
Nancy
Compiègne
Kuopio
Brignoles
Helsinki
Hyvinkää
Mallow
Drogheda
Stockholm
Stockholm
Stockholm
Lead Sponsor
Bayer
INDUSTRY